Peramivir: An intravenous neuraminidase inhibitor

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 12, 2015, Pages 1889-1900

  Mclaughlin, Milena M ^a,b   Skoglund, Erik W ^a   Ison, Michael G ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

influenza; neuraminidase inhibitor; oseltamivir; peramivir; zanamivir

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; SIALIDASE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLUENZA; KIDNEY DISEASE; MEDICATION COMPLIANCE; MYASTHENIA GRAVIS; NONHUMAN; PETECHIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; NEURAMINIDASE;

EID: 84937710577     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1066336     Document Type: Article

References (78)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-Associated hospitalizations in the United States. JAMA 2004; 11(292): 1333-40
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 2(289): 179-86
3. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-Associated deaths made using four different methods. Influenza Other Respir Viruses 2009; 1(3): 37-49
4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361(20): 1935-44
5. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 25(360): 2605-15
6. Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2008; 10(29): 921-6
7. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007; 4(167): 354-60
8. Ison MG. Influenza in hospitalized adults: gaining insight into a significant problem. J Infect Dis 2009; 4(200): 485-8
9. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 3(8): 183-90
10. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenzarelated lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 14(163): 1667-72
11. Lee N, Chan KS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 4(200): 492-500
12. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 4(12): 501-8
13. Leekha S, Zitterkopf NL, Espy MJ, et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 9(28): 1071-6
14. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario. Canada. Clin Infect Dis 2007; 12(45): 1568-75
15. Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 2007; 7(195): 1029-37
16. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 17(302): 1872-9
17. Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009; 17(302): 1888-95
18. Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 20(361): 1925-34
19. GlaxoSmithKline. Relenza inhalation powder must not be nebulized. healthcare provider letter. 2009. Available from: http://www.fda. gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM186224.pdf [Last accessed on 11 March 2015]
20. Chand P, Kotian PL, Dehghani A, et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J Med Chem 2001; 25(44): 4379-92
21. Taylor NR, von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem 1994; 5(37): 616-24
22. Bossart-Whitaker P, Carson M, Babu YS, et al. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2, 3-dehydro-N-Acetyl neuraminic acid. J Mol Biol 1993; 4(232): 1069-83
23. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 19(43): 3482-6
24. Bantia S, Parker CD, Ananth SL, et al.comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 4(45): 1162-7
25. Govorkova EA, Leneva IA, Goloubeva OG, et al.comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 10(45): 2723-32
26. Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 2002; 4(46): 1014-21
27. Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 1(69): 39-45
28. Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 15(77): 8418-25
29. Cao RY, Xiao JH, Cao B, et al. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 2014; 6(23): 237-40
30. Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 3(73): 228-31
31. Stoner TD, Krauss S, DuBois RM, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 2010; 19(84): 9800-9
32. Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008; 2(80): 150-7
33. Drusano GL, Preston SL, Smee D, et al. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001; 7(45): 2115-18
34. Sidwell RW, Bailey KW, Morrey JD, et al. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res 2003; 1(60): 17-25
35. Sidwell RW, Smee DF, Huffman JH, et al. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res 2001; 3(51): 179-87
36. Sweet C, Jakeman KJ, Bush K, et al. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 2002; 4(46): 996-1004
37. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 1(374): 198-209
38. Sidwell RW, Smee DF, Huffman JH, et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001; 3(45): 749-57
39. Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 2002; 6(11): 859-69
40. Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4: 2854
41. Kitano M, Itoh Y, Ishigaki H, et al. Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob Agents Chemother 2014; 8(58): 4795-803
42. Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci 2001; 1416(356): 1905-13
43. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005; 8(10): 901-10
44. Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther 2014
45. BioCryst Pharmaceuticals, Inc Press Release. BioCryst provides peramivir update and reports first quarter 2009 financial results. 2009. Available from: http://www.prnewswire.com/news-releases/biocrystprovides-peramivir-update-And-reportsfirst-quarter-2009-financial-results-61796982.html [Last accessed on 12 March 2015]
46. Kohno S, Kida H, Mizuguchi M, Shimada J. S-021812 Clinical Study Group A double-blind, placebocontrolled study of intravenous peramivir in acute influenza patients. IDSA-ICAAC Annual Meeting 2008; Abstract V-4154a. Conference Paper . The abstract that documents the Phase II single dose IV peramivir study in ambulatory adults in Asia
47. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 11(55): 5267-76
48. Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy 2013; 5(59): 373-8
49. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 6(55): 2803-12
50. Ison MG, Mcgeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. XI International Symposium on Respiratory Viral Infections 2009; Conference Paper
51. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014; 12(59): e172-85
52. Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence. Expert Rev Anti Infect Ther 2015; 4(13): 417-25
53. Martin-Loeches I, Diaz E, Vidaur L, et al. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care 2011; 6(15): R286
54. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 9(55): 1198-204
55. Food and Drug Administration. Emergency use authorization of peramivir IV fact sheet for health care providers. 2009. Available from: http://www.fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/UCM187811.pdf [Last accessed on 12 March 2015]
56. Hayashi K, Iwasa K, Morinaga A, et al. Exacerbation of myasthenia gravis by intravenous peramivir. Muscle Nerve 2015; 51(6): 935-6
57. Harada-Shirado K, Ikeda K, Furukawa M, et al. Severe immune thrombocytopenia possibly elicited by the anti-influenza viral agent peramivir. Intern Med 2014; 20(53): 2369-71
58. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 24(368): 2277-85
59. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 9885(381): 2273-9
60. Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-Treated patient in Taiwan. J Infect Dis 2015; 2(211): 249-57
61. Tang X, He H, Sun B, et al. ARDS associated with pneumonia caused by avian influenza A H7N9 virus treated with extracorporeal membrane oxygenation. Clin Respir J 2014
62. Yang ZF, Mok CK, Liu XQ, et al. Clinical, Virological and Immunological Features from Patients Infected with Re-Emergent Avian-Origin Human H7N9 Influenza Disease of Varying Severity in Guangdong Province. PLoS One 2015; 2(10): e0117846
63. Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous antiinfluenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation. J Infect Chemother 2015; 3(21): 194-201
64. Sugaya N, Kohno S, Ishibashi T, et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012; 1(56): 369-77
65. Scheetz MH, Griffith MM, Ghossein C, et al. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. Ann Pharmacother 2011; 12(45): e64
66. Bentley ML, Hollistera AS, Hansenb AC, et al. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. Int J Clin Pharmacol Ther 2014; 12(52): 1105-11
67. Ison MG. Anti-influenza therapy: The emerging challenge of resistance. Therapy 2009; 6(6): 883-91
68. Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 2014; 110: 31-41
69. Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivirresistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 1(83): 90-3
70. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 11(49): 4515-20
71. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 8(11): 971-6
72. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir-And peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 9(50): 1252-5
73. Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother 2010; 7(54): 2819-22
74. Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous antiinfluenza neuraminidase inhibitor peramivir (I): a drug use investigation. J Infect Chemother 2014; 11(20): 689-95
75. Birnkrant D, Cox E. The Emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361(23): 2204-7
76. Rapivab (peramivir) [package insert]. BioCryst Pharmaceuticals Inc., Birmingham, AL; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206426lbl.pdf [Last accessed on 11 March 2015]
77. Sleeman K, Guo Z, Barnes J, et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 9(19): 1521-4
78. Center for Drug Evaluation and Research. Summary Review of Peramivir. Application Number: 206426Orig1s000. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2014/206426Orig1s000SumR.pdf [Last accessed on 11 March 2015